aboratory measurement of direct oral anticoagulants on patients with atrial fibrillation.
Phase 1
- Conditions
- on-valvular atrial fibrillationTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- EUCTR2016-002105-18-FI
- Lead Sponsor
- Helsinki City Hospital Haartman
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who present with atrial fibrillation.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 50
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100
Exclusion Criteria
Valvular atrial fibrillation (mechanical heart valve or mitral stenosis), active malignancy, contraindication to anticoagulation (eg. severe bleeding tendency), severe thrombophilia (eg. lupus anticoagulant).
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method